In the phase I trial of advanced solid tumors, one patient with BRAF-mutated PTC during part A and three patients, including two BRAF-mutated melanoma and one BRAF wild-type melanoma in part B, had PR [126]. The gene discussed is BRAF; the disease is melanoma.